UBXN6 Antibody

What is UBXN6 and what cellular functions does it regulate?

UBXN6, also known as UBXD1 or UBX domain-containing protein 6, serves as a cofactor for VCP, an ATP-driven segregase associated with diverse cellular activities. UBXN6 plays multiple critical roles in cellular homeostasis, including:

• Negative regulation of VCP ATPase activity, modulating its segregase function

• Facilitation of CAV1 transport to lysosomes for degradation

• Participation in endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins

• Regulation of macroautophagy, particularly in damaged lysosome clearance

• Activation of autophagy pathways and regulation of inflammatory responses

• Maintenance of immune system suppression during sepsis

Recent research has demonstrated that UBXN6 upregulation in sepsis patients negatively correlates with inflammatory gene profiles but positively correlates with autophagy-related genes, suggesting an immunomodulatory function in inflammatory conditions .

Which cell types primarily express UBXN6 and how can this expression be detected?

Single-cell RNA sequencing (scRNA-seq) analysis has revealed that UBXN6 is predominantly expressed in monocytes/macrophages rather than in T or B cells . This cell-specific expression pattern is particularly significant when studying UBXN6 in immune-related contexts.

UBXN6 expression can be detected through multiple techniques:

• Western blotting: The predicted band size for UBXN6 is 49 kDa

• Immunofluorescence: Effective in PFA-fixed/Triton X-100 permeabilized cells at 4 μg/ml concentration

• qRT-PCR: For measuring UBXN6 mRNA expression levels

• RNA-seq/scRNA-seq: For transcriptome-wide expression analysis

When using immunofluorescence, UBXN6 displays a characteristic intracellular distribution pattern that can be visualized with appropriate antibodies, as demonstrated in studies using HEK293 cells .

What are the common applications of UBXN6 antibodies in research?

Based on validated research protocols, UBXN6 antibodies are commonly used in:

• Western blotting (WB): Typically used at 1/500 dilution, effective for detecting UBXN6 in various cell lysates including RT4 and U251 MG cells

• Immunocytochemistry/Immunofluorescence (ICC/IF): Used successfully for cellular localization studies

• Inflammation research: Particularly for studying monocyte/macrophage responses to inflammatory stimuli

• Autophagy studies: Investigating UBXN6's role in autophagy activation and regulation

• Protein-protein interaction studies: Examining UBXN6's function as a VCP cofactor

These applications have been validated for human samples, with antibodies typically generated against recombinant fragment proteins within the N-terminal (aa 1-100) region of human UBXN6 .

What experimental approaches are used to study UBXN6 function?

Multiple complementary approaches are employed to investigate UBXN6 function:

Research has shown that myeloid-specific UBXN6 deficiency leads to exacerbated inflammation, increased oxidative stress, and impaired autophagy, highlighting the protein's importance in immune regulation .

What are the optimal experimental conditions for detecting UBXN6 using immunofluorescence?

For optimal immunofluorescence detection of UBXN6, researchers should consider the following protocol parameters:

• Fixation: 4% paraformaldehyde (PFA) has been successfully used in published protocols

• Permeabilization: Triton X-100 is effective for accessing intracellular UBXN6

• Antibody concentration: 4 μg/ml has been validated for UBXN6/UBXD1 antibody (ab221167)

• Visualization: Green fluorescence channel is typically used for detection

When working with monocytes/macrophages, which express higher levels of UBXN6, consider these additional factors:

• Cell adherence: Ensure proper attachment to appropriate substrates

• Autofluorescence: Macrophages may exhibit higher background that requires appropriate compensation

• Co-staining: Consider using monocyte/macrophage markers (CD14, FCGR3A, LYZ, MS4A7) for cell identification

• Controls: Include UBXN6-deficient cells as negative controls to confirm antibody specificity

The subcellular localization pattern can provide insights into UBXN6 function in different cellular compartments, particularly in relation to autophagy and ERAD pathways.

How can researchers effectively validate UBXN6 antibody specificity?

Rigorous validation is essential for reliable UBXN6 detection. Consider these approaches:

• Genetic validation:

  • Use UBXN6-deficient models (knockout mice or knockdown cells) as negative controls

  • Perform rescue experiments with UBXN6 re-expression to confirm specificity

• Application-specific validation:

  • For Western blotting: Verify the band at the predicted 49 kDa size

  • For immunofluorescence: Compare staining pattern with published literature

  • For both: Confirm absence of signal in knockout/knockdown samples

• Cross-antibody validation:

  • Use multiple antibodies targeting different UBXN6 epitopes

  • Compare results across techniques (WB, IF, IP)

• Expression pattern consistency:

  • Confirm higher expression in monocytes/macrophages compared to lymphocytes

  • Validate cell-type specific expression patterns across different samples

Successful antibody validation should demonstrate consistent results across multiple experimental systems while showing appropriate differences between control and UBXN6-deficient samples.

What methodological approaches can be used to study UBXN6's role in autophagy pathways?

UBXN6 serves as an activator of autophagy, and several methodological approaches can elucidate its function:

• Autophagy flux assessment:

  • Monitor LC3-I to LC3-II conversion by Western blot

  • Evaluate p62/SQSTM1 degradation as an autophagy completion marker

  • Use autophagy inhibitors (bafilomycin A1, chloroquine) to distinguish induction from blockade

• Genetic manipulation approaches:

  • Compare autophagy markers between wild-type and UBXN6-deficient cells or tissues

  • Assess interaction between UBXN6 and core autophagy machinery

  • Examine downstream effects on TFEB nuclear translocation, which is impaired in UBXN6-deficient cells

• Microscopy techniques:

  • Transmission electron microscopy (TEM) to visualize autophagic structures and mitochondrial damage

  • Confocal microscopy to assess co-localization with autophagy markers

  • Live-cell imaging to monitor dynamics of autophagosome formation

• Pathway analysis:

  • Examine mTOR pathway activation, which is enhanced in UBXN6-deficient cells

  • Evaluate FOXO3 expression, which positively correlates with UBXN6 in sepsis patients

  • Assess lysosomal biogenesis markers, which are reduced with UBXN6 deficiency

Research has demonstrated that UBXN6 deficiency leads to immunometabolic remodeling, characterized by a shift to aerobic glycolysis and elevated branched-chain amino acids, amplifying mTOR signaling and impairing autophagy .

What considerations are important when using UBXN6 antibodies in inflammatory condition studies?

When investigating UBXN6 in inflammatory contexts such as sepsis, researchers should consider:

• Expression dynamics:

  • UBXN6 is upregulated in humans with sepsis

  • Expression correlates negatively with inflammatory gene profiles but positively with autophagy genes

  • Time-dependent expression changes may occur during disease progression

• Cell type specificity:

  • Focus on monocytes/macrophages where UBXN6 is predominantly expressed

  • Consider isolating specific immune cell populations before analysis

  • Use cell type-specific markers to identify UBXN6-expressing cells in mixed populations

• Functional context:

  • UBXN6 regulates multiple inflammatory pathways including NLRP3 inflammasome activation

  • Design experiments to assess canonical and non-canonical inflammasome pathways

  • Evaluate both acute inflammatory responses and immunosuppressive phases

• Tissue-specific effects:

  • Different tissues show variable responses to UBXN6 deficiency (e.g., increased inflammation in lungs and spleen but not liver)

  • Design tissue-specific analyses for comprehensive understanding

• Model selection:

  • Different models (LPS challenge, CLP, secondary infection) reveal distinct aspects of UBXN6 function

  • The two-hit model (CLP followed by secondary bacterial infection) is particularly useful for studying immunosuppression

Research has shown that myeloid-specific UBXN6 deficiency increases susceptibility to LPS-induced mortality but paradoxically improves resistance to secondary bacterial infection following CLP, highlighting its complex role in inflammation regulation .

What experimental models are most suitable for studying UBXN6's role in inflammation?

Based on published research, the following experimental models are effective for studying UBXN6:

When selecting models, researchers should consider:

• The specific aspect of inflammation being studied (acute vs. chronic, systemic vs. local)

• The relevant cell types involved (focusing on monocytes/macrophages)

• The downstream pathways of interest (inflammasome activation, autophagy, oxidative stress)

• The translational relevance to human disease

These models have revealed that UBXN6 plays a dual role: restricting excessive inflammation during acute responses while potentially contributing to immunosuppression during prolonged septic conditions .

How can researchers reconcile contradictory findings regarding UBXN6 function?

Resolving contradictory findings about UBXN6 requires careful methodological consideration:

Research has demonstrated that while UBXN6 deficiency exacerbates acute inflammation and increases mortality in LPS challenge models, it paradoxically improves resistance to secondary infection in a CLP model, highlighting its complex, context-dependent functions in inflammation regulation .